Cresset Asset Management LLC lessened its stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 64.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,460 shares of the medical instruments supplier's stock after selling 20,567 shares during the quarter. Cresset Asset Management LLC's holdings in DENTSPLY SIRONA were worth $219,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its stake in shares of DENTSPLY SIRONA by 15,105.1% in the 4th quarter. Pacer Advisors Inc. now owns 4,503,591 shares of the medical instruments supplier's stock valued at $85,478,000 after purchasing an additional 4,473,972 shares during the last quarter. Nuance Investments LLC lifted its position in shares of DENTSPLY SIRONA by 25.0% in the fourth quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier's stock worth $257,103,000 after purchasing an additional 2,708,097 shares in the last quarter. Norges Bank bought a new stake in shares of DENTSPLY SIRONA in the fourth quarter worth $45,730,000. AQR Capital Management LLC lifted its position in shares of DENTSPLY SIRONA by 245.1% in the fourth quarter. AQR Capital Management LLC now owns 2,893,023 shares of the medical instruments supplier's stock worth $54,389,000 after purchasing an additional 2,054,767 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of DENTSPLY SIRONA by 18.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier's stock worth $238,186,000 after purchasing an additional 1,975,404 shares in the last quarter. Institutional investors and hedge funds own 95.70% of the company's stock.
DENTSPLY SIRONA Trading Down 2.4%
NASDAQ XRAY traded down $0.38 during trading hours on Friday, reaching $15.47. The company's stock had a trading volume of 2,475,144 shares, compared to its average volume of 2,968,748. The firm has a fifty day simple moving average of $14.47 and a 200-day simple moving average of $17.08. The stock has a market cap of $3.08 billion, a P/E ratio of -7.47, a P/E/G ratio of 1.80 and a beta of 0.92. DENTSPLY SIRONA Inc. has a 52 week low of $12.16 and a 52 week high of $28.25. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.25 and a quick ratio of 0.84.
DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $0.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.14. The business had revenue of $879.00 million during the quarter, compared to analyst estimates of $854.75 million. DENTSPLY SIRONA had a negative net margin of 10.59% and a positive return on equity of 12.62%. The firm's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the business earned $0.42 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.
DENTSPLY SIRONA Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, April 11th. Shareholders of record on Friday, March 28th were issued a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, March 28th. This represents a $0.64 annualized dividend and a yield of 4.14%. DENTSPLY SIRONA's payout ratio is -14.10%.
Insiders Place Their Bets
In other news, Director Gregory T. Lucier purchased 15,142 shares of the stock in a transaction on Monday, March 3rd. The stock was purchased at an average price of $16.51 per share, for a total transaction of $249,994.42. Following the acquisition, the director now owns 81,971 shares in the company, valued at $1,353,341.21. This trade represents a 22.66% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.52% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the stock. Mizuho cut their price objective on shares of DENTSPLY SIRONA from $21.00 to $18.00 and set a "neutral" rating on the stock in a research report on Thursday, March 13th. Needham & Company LLC reaffirmed a "hold" rating on shares of DENTSPLY SIRONA in a research report on Thursday, March 13th. Wall Street Zen upgraded shares of DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Piper Sandler decreased their price target on shares of DENTSPLY SIRONA from $20.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 30th. Finally, UBS Group reduced their price objective on shares of DENTSPLY SIRONA from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Eleven equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, DENTSPLY SIRONA has an average rating of "Hold" and a consensus target price of $20.36.
Get Our Latest Analysis on DENTSPLY SIRONA
DENTSPLY SIRONA Profile
(
Free Report)
DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.
Recommended Stories
Before you consider DENTSPLY SIRONA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.
While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
